Update of the MDS research criteria for prodromal Parkinson's disease

被引:479
|
作者
Heinzel, Sebastian [1 ]
Berg, Daniela [1 ]
Gasser, Thomas [2 ]
Chen, Honglei [3 ]
Yao, Chun [4 ]
Postuma, Ronald B. [4 ]
Adler, Charles H.
Bloem, Bastiaan
Chan, Piu
Deuschl, Guenther
Dubois, Bruno
Goetz, Christopher G.
Halliday, Glenda M.
Hardy, John
Lang, Anthony E.
Litvan, Irene
Marek, Kenneth
Obeso, Jose
Oertel, Wolfgang
Olanow, C. Warren
Poewe, Werner
Stern, Matthew
机构
[1] Univ Kiel, Dept Neurol, Arnold Heller Str 3, D-24105 Kiel, Germany
[2] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat, Tubingen, Germany
[3] Michigan State Univ, Coll Human Med, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA
[4] Montreal Gen Hosp, Dept Neurol, L7-305,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada
关键词
Parkinson's disease; prodromal; evidence-based; Bayesian classifier; risk marker; ALPHA-SYNUCLEIN DEPOSITS; SLEEP BEHAVIOR DISORDER; PHYSICAL-ACTIVITY; PLASMA URATE; FAMILIAL AGGREGATION; ATHEROSCLEROSIS RISK; FUTURE RISK; ASSOCIATION; PENETRANCE; MUTATION;
D O I
10.1002/mds.27802
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The MDS Research Criteria for Prodromal PD allow the diagnosis of prodromal Parkinson's disease using an evidence-based conceptual framework, which was designed to be updated as new evidence becomes available. New prospective evidence of predictive values of risk and prodromal markers published since 2015 was reviewed and integrated into the criteria. Many of the predictive values (likelihood ratios, LR) remain unchanged. The positive likelihood ratio notably increase for olfactory loss and decreased for substantia nigra hyperechogenicity. Negative likelihood ratio remained largely unchanged for all markers. New levels of diagnostic certainty for neurogenic and symptomatic orthostatic hypotension have been added, which substantially differ in positive likelihood ratio from the original publication. For intermediate strength genetic variants, their age-related penetrance is now incorporated in the calculation of the positive likelihood ratio. Moreover, apart from prospective studies, evidence from cross-sectional case-control genome-wide association studies is also considered (given their likely lack of confounding and reverse causation), and to account for the effect of multiple low-penetrance genetic variants polygenic risk scores are added to the model. Diabetes, global cognitive deficit, physical inactivity, and low plasma urate levels in men enter the criteria as new markers. A web-based prodromal PD risk calculator allows the calculation of probabilities of prodromal PD for individuals. Several promising candidate markers may improve the diagnostic accuracy of prodromal PD in the future. (c) 2019 International Parkinson and Movement Disorder Society
引用
收藏
页码:1464 / 1470
页数:7
相关论文
共 50 条
  • [21] Validation of the MDS Clinical Diagnostic Criteria for Parkinson's Disease
    Postuma, Ronald
    Poewe, Werner
    Litvan, Irene
    Lewis, Simon
    Lang, Anthony
    Halliday, Glenda
    Goetz, Christopher
    Chan, Piu
    Slow, Elizabeth
    Seppi, Klaus
    Schaeffer, Eva
    Berg, Daniela
    Romenets, Silvia Rios
    Mi, Taomian
    Maetzler, Corina
    Li, Yuan
    Heim, Beatrice
    Bledsoe, Ian
    NEUROLOGY, 2018, 90
  • [22] Testing the MDS clinical diagnostic criteria for Parkinson's disease
    Schrag, Anette
    MOVEMENT DISORDERS, 2018, 33 (10) : 1518 - 1520
  • [23] Prodromal Parkinson's disease
    Trenkwalder, Claudia
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [24] Application of the Movement Disorder Society Prodromal Parkinson's Disease Research Criteria in 2 Independent Prospective Cohorts
    Pilotto, Andrea
    Heinzel, Sebastian
    Suenkel, Ulrike
    Lerche, Stefanie
    Brockmann, Kathrin
    Roeben, Benjamin
    Schaeffer, Eva
    Wurster, Isabel
    Yilmaz, Rezzak
    Liepelt-Scarfone, Inga
    von Thaler, Anna-Katharina
    Metzger, Florian G.
    Eschweiler, Gerhard W.
    Postuma, Ron B.
    Maetzler, Walter
    Berg, Daniela
    MOVEMENT DISORDERS, 2017, 32 (07) : 1025 - 1034
  • [25] MDS study group validation of MDS criteria for mild cognitive impairment in Parkinson's disease
    Boel, J. A.
    Hoogland, J.
    Goldman, J. G.
    Schmand, B. A.
    Troster, A. I.
    Burn, D. J.
    Litvan, I.
    Geurtsen, G. J.
    MOVEMENT DISORDERS, 2014, 29 : S339 - S339
  • [26] Caveats of Neurodegenerative Risk Stratification in Idiopathic REM Sleep Behavior Disorder by Use of the MDS Research for Prodromal Parkinson's Disease
    Mahlknecht, Philipp
    Iranzo, Alex
    Stefani, Ambra
    Serradell, Monica
    Santamaria, Joan
    Tolosa, Eduardo
    Hogl, Birgit
    Poewe, Werner
    SLEEP, 2017, 40 (10)
  • [27] Prodromal diagnosis of Parkinson's disease
    Montgomery, Erwin B., Jr.
    MOVEMENT DISORDERS, 2012, 27 (11) : 1467 - 1467
  • [28] Psychosis in Prodromal Parkinson's disease
    Pachi, I.
    Maraki, M.
    Kosmidis, M.
    Yannakoulia, M.
    Dardiotis, E.
    Hadjigeorgiou, G.
    Sakka, P.
    Xiromerisiou, G.
    Stamelou, M.
    Scarmeas, N.
    Stefanis, L.
    MOVEMENT DISORDERS, 2019, 34 : S154 - S154
  • [29] Editorial: Prodromal Parkinson's Disease
    Crosiers, David
    Santens, Patrick
    Chaudhuri, K. Ray
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [30] The Concept of Prodromal Parkinson's Disease
    Mahlknecht, Philipp
    Seppi, Klaus
    Poewe, Werner
    JOURNAL OF PARKINSONS DISEASE, 2015, 5 (04) : 681 - 697